BioNxt Completes Fast-Track Patent Filing for MS Treatment

Vancouver-based BioNxt Solutions Inc. has announced the completion of a priority patent filing with the U.S. Patent and Trademark Office. The filing concerns a sublingual thin-film cladribine formulation (BNT23001) intended for multiple sclerosis (MS) treatment. This fast-track application aims to secure U.S. patent protection and fortify BioNxt's intellectual property as it prepares for bioequivalence studies and partnerships.

The filing also opens avenues for treating other neurological autoimmune diseases. The patent nationalization process is ongoing in markets such as the EU, U.S., and Canada. Favorable feedback from European and Eurasian patent offices underscores the innovation's scientific and commercial value.

BNT23001 offers a sublingual delivery method, promoting faster action and improved compliance, essential for patients seeking alternatives to traditional forms.